CWA Asset Management Group LLC Acquires New Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

CWA Asset Management Group LLC acquired a new position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 66,275 shares of the company's stock, valued at approximately $292,000.

A number of other institutional investors also recently bought and sold shares of GDRX. Geode Capital Management LLC grew its position in GoodRx by 9.1% in the 4th quarter. Geode Capital Management LLC now owns 1,071,761 shares of the company's stock valued at $4,986,000 after buying an additional 89,032 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of GoodRx in the 4th quarter worth $358,000. Barclays PLC boosted its holdings in shares of GoodRx by 18.4% in the fourth quarter. Barclays PLC now owns 165,928 shares of the company's stock valued at $772,000 after acquiring an additional 25,815 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of GoodRx by 13.5% in the fourth quarter. Northern Trust Corp now owns 421,810 shares of the company's stock valued at $1,961,000 after acquiring an additional 50,256 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of GoodRx by 10.1% during the fourth quarter. Bank of New York Mellon Corp now owns 192,612 shares of the company's stock worth $896,000 after acquiring an additional 17,633 shares during the period. 63.77% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on GDRX. Truist Financial reduced their price objective on shares of GoodRx from $6.50 to $5.50 and set a "hold" rating for the company in a research report on Thursday, April 10th. UBS Group cut their target price on GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. The Goldman Sachs Group decreased their price target on GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. Finally, Wells Fargo & Company dropped their price objective on GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th. Five research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, GoodRx has a consensus rating of "Moderate Buy" and an average target price of $6.55.

Insider Activity

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business's stock in a transaction on Friday, June 6th. The stock was sold at an average price of $4.09, for a total value of $43,668.93. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 4.53% of the company's stock.

GoodRx Price Performance

GDRX traded down $0.16 during trading on Wednesday, reaching $4.91. 2,050,431 shares of the stock were exchanged, compared to its average volume of 1,410,518. The company has a debt-to-equity ratio of 0.74, a current ratio of 5.23 and a quick ratio of 5.23. The company has a market capitalization of $1.75 billion, a price-to-earnings ratio of 36.21, a P/E/G ratio of 2.25 and a beta of 1.16. GoodRx Holdings, Inc. has a 1 year low of $3.68 and a 1 year high of $9.26. The business's 50 day moving average price is $4.29 and its two-hundred day moving average price is $4.51.

GoodRx (NASDAQ:GDRX - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.04 by $0.05. GoodRx had a net margin of 3.57% and a return on equity of 7.85%. The business had revenue of $202.97 million for the quarter, compared to analyst estimates of $202.25 million. During the same period in the previous year, the firm earned $0.08 EPS. The business's revenue for the quarter was up 2.6% compared to the same quarter last year. As a group, equities research analysts anticipate that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.